BeOne Medicines Ltd. (BEIGF) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-05-15

Key Insights

SVP and General Counsel Lee Chan Henry executed a net sale of 332 ADS (4,316 ordinary shares) on 05/13/2026 at $310.72/share, generating approximately $103,279 in proceeds, pursuant to a Rule 10b5-1 trading plan adopted on May 14, 2025.
Insider simultaneously acquired 532 ADS (6,916 ordinary shares) across three separate transactions on the same day at varying prices ($194.47-$213.32), suggesting opportunistic buying while executing pre-planned sales under the 10b5-1 plan.
Officer holds significant unvested equity compensation with 4,316 in-the-money options (exercise prices ranging $12.23-$16.41) vesting through 2034, indicating long-term alignment with company performance despite recent sales activity.
The pre-planned nature of the sale (Rule 10b5-1 plan adopted one year prior) suggests this transaction was scheduled rather than reactive to company developments, limiting inference about insider confidence levels.

Want the newest filings?

This analysis covers the filing from 2026-05-15. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-04-10

The reporting person, Henry Lee Chan, who is the SVP and General Counsel of BeOne Medicines Ltd. (BEIGF), has exercised and sold a significant number of stock options and American Depositary Shares (ADSs) over the past few days.
The timing of the option exercises and stock sales suggests that the reporting person may have been monetizing their equity compensation, potentially due to an upcoming liquidity event or personal financial needs.
The reported transactions do not appear to be part of a regular selling plan, which could raise some concerns about the reporting person's confidence in the company's future prospects.

Filed: 2026-03-10

The Chief Financial Officer, Aaron Rosenberg, acquired a significant number of ordinary shares in BeOne Medicines, suggesting confidence in the company's future performance.
The shares were granted as performance share units, indicating that Rosenberg's compensation is tied to the company's long-term success through vesting conditions.
The acquisition of these shares, which are set to vest in 2027 and 2028, aligns Rosenberg's interests with those of the company and its shareholders.

Filed: 2026-03-10

The reporting person, Wu Xiaobin, acquired 168,922 and 78,624 ordinary shares of BeOne Medicines Ltd. through performance share units that will vest in 2027 and 2028 respectively, indicating the company's confidence in his leadership as President and COO.
The reporting person also holds 12,365 American Depositary Shares (ADS) directly and 4,000 ADS indirectly through his wife, representing a significant ownership stake in the company.
The large amount of shares acquired by the reporting person, and the vesting schedule of the performance share units, suggest a long-term commitment to the company's success.

Filed: 2026-03-10

President and Global Head of R&D Wang Lai acquired a substantial number of 167,635 ordinary shares through performance share units, indicating strong alignment with the company's long-term success.
Wang Lai holds a significant indirect beneficial ownership of 601,965 ordinary shares through Wang Holdings LLC, suggesting strong insider commitment.
The company established an employee participation program to allow certain executives and employees to indirectly purchase RMB shares, providing additional alignment with shareholders.

Filed: 2026-03-10

The reporting person, Henry Lee, was granted a total of 95,264 ordinary shares of BeOne Medicines through performance share units, which will vest in 2027 and 2028 subject to his continued service.
The reporting person's total beneficial ownership of BeOne Medicines shares has increased to 318,370, indicating a significant increase in his equity stake in the company.
The vesting of the performance share units is subject to accelerated vesting upon certain termination events, suggesting the company's intention to incentivize and retain key personnel.

Filed: 2026-03-10

Reporting person John Oyler, the CEO of BeOne Medicines Ltd., has acquired a significant number of the company's ordinary shares, both directly and through various trust and investment vehicles.
The acquired shares include performance share units that will vest in 2027 and 2028, subject to continued service, as well as shares held indirectly through family trusts and investment vehicles.
The insider buying activity by the CEO suggests a positive outlook and commitment to the company, which could be of interest to investors.

Filed: 2026-02-06

The reporting person, Henry Lee Chan, is the SVP and General Counsel of BeOne Medicines Ltd. (BEIGF), indicating a key leadership position within the company.
Lee Chan exercised several stock options and sold a portion of his American Depositary Shares (ADSs), potentially suggesting some asset diversification or liquidity needs.
The option exercise prices, vesting schedules, and trading plan disclosures provide insight into Lee Chan's equity compensation and alignment with shareholder interests.

Filed: 2026-01-09

The reporting person, Henry Lee Chan, SVP and General Counsel of BeOne Medicines Ltd. (BEIGF), exercised several stock options and sold a portion of the acquired shares.
The transactions were made pursuant to a 10b5-1 trading plan, indicating planned insider selling activity.
The reporting person continues to hold a significant number of vested stock options, suggesting ongoing equity incentive alignment with the company's performance.

Other reports for BeOne Medicines Ltd.

Current Report Quarterly Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.